Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Asia Saorin, Emanuela Di Gregorio, Angela Buonadonna, Gianmaria Miolo, Giuseppe Corona
Summary: This study investigated the change in lipid composition in sebum during cetuximab-based treatment and found that cetuximab administration led to a decrease in sebum production, particularly in triglycerides and squalene content. The reduction of these lipid classes was associated with the severity of skin rash experienced by patients.
Article
Oncology
Pui Lam Yip, Wai Him Brian Fung, Francis Ann Shing Lee, Chak Fei Lee, Natalie Sean Man Wong, Shing Fung Lee
Summary: This retrospective study reports the real-world effectiveness and safety of modified CAPIRI-P (mCAPIRI-P) regimen in patients with metastatic colorectal cancer. The results show that mCAPIRI-P is a safe and effective first-line treatment for RAS wild-type advanced colorectal cancer, and further research is warranted.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yoshitaka Saito, Kazuki Uchiyama, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: A retrospective evaluation of mCRC patients receiving anti-EGFR monoclonal antibody treatment identified liver metastasis as an independent risk factor for skin toxicities and prophylactic administration of antibiotics as a preventive factor. The study suggests that preemptive antibiotic use can decrease the risk of skin toxicities during anti-EGFR treatment.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Medicine, General & Internal
Rona Yaeger, Jared Weiss, Meredith S. Pelster, Alexander Spira, Minal Barve, Sai-Hong Ou, Ticiana A. Leal, Tanios S. Bekaii-Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der-Torossian, Samuel J. Klempner
Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Yasmin Cura, Almudena Sanchez-Martin, Noelia Marquez-Pete, Encarnacion Gonzalez-Flores, Fernando Martinez-Martinez, Cristina Perez-Ramirez, Alberto Jimenez-Morales
Summary: This study evaluated the association of SNPs with severe toxicity and treatment suspension in colorectal cancer patients treated with Capecitabine-based therapy. SNPs CES1 rs71647871 and CDA rs1048977 were identified as potential predictive biomarkers of treatment safety.
Review
Pharmacology & Pharmacy
Zaina T. Al-Salama
Summary: Encorafenib in combination with cetuximab has shown significantly longer overall survival, higher response rate, and better tolerability in patients with mCRC and a BRAF V600E mutation who have had prior therapy.
Article
Medicine, Research & Experimental
Janine Ziemons, Romy Aarnoutse, Anne Heuft, Lars Hillege, Janneke Waelen, Judith de Vos-Geelen, Liselot Valkenburg-van Iersel, Irene E. G. van Hellemond, Geert-Jan M. Creemers, Arnold Baars, Johanna H. M. J. Vestjens, John Penders, Koen Venema, Marjolein L. L. Smidt
Summary: This study investigated the effect of capecitabine treatment on fecal levels of SCFA and BCFA in colorectal cancer patients. The results showed a significant decrease in valerate and caproate levels during treatment, and a association between baseline iso-butyrate levels and tumor response. Nutritional status, physical performance, and chemotherapy-induced toxicity were not significantly associated with SCFA or BCFA.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Oncology
Matthew Fowler, Helene Tobback, Alice Karuri, Paz Fernandez-Ortega
Summary: Encorafenib, a BRAF inhibitor, in combination with cetuximab, an EGFR inhibitor, has been approved for the treatment of BRAF(V600E)-mutant metastatic colorectal cancer. Nurses play a crucial role in managing the care of these patients, including early identification and management of treatment-related adverse events, as well as educating patients and caregivers about these events.
SUPPORTIVE CARE IN CANCER
(2023)
Review
Immunology
Balakarthikeyan Janani, Mayakrishnan Vijayakumar, Kannappan Priya, Jin Hee Kim, D. S. Prabakaran, Mohammad Shahid, Sameer Al-Ghamdi, Mohammed Alsaidan, Nasraddin Othman Bahakim, Mohammad Hassan Abdelzaher, Thiyagarajan Ramesh
Summary: Colorectal carcinoma is a common and lethal form of cancer, with a high rate of metastasis. Targeted nanotherapy, particularly targeting EGFR, has the potential to improve surgical control and reduce tumor-related mortality. Antibodies conjugated with drug-loaded carriers can increase drug effectiveness and quantity delivered to the target site.
Article
Medicine, General & Internal
Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero
Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Cell Biology
Hong Lu, Hao Zhang, Mei-lin Weng, Jin Zhang, Nan Jiang, Juan P. Cata, Duan Ma, Wan-Kun Chen, Chang-Hong Miao
Summary: Morphine treatment can activate MOR and promote proliferation, migration, and invasion in CRC cells, as well as increase resistance to cetuximab. It induces EGFR transactivation, leading to protumoral effects in CRC cell lines.
JOURNAL OF CELLULAR PHYSIOLOGY
(2021)
Article
Oncology
Alexey V. Sorokin, Preeti Kanikarla Marie, Lea Bitner, Muddassir Syed, Melanie Woods, Ganiraju Manyam, Lawrence N. Kwong, Benny Johnson, Van K. Morris, Philip Jones, David G. Menter, Michael S. Lee, Scott Kopetz
Summary: This study evaluates the therapeutic efficacy and safety of combined MEK-CDK4/6 inhibition in RAS mutant colorectal cancer using patient-derived xenografts and clinical trials, identifies biomarkers of response, and uncovers targetable mechanisms of resistance.
Article
Oncology
Jiawei Zhou, Quefeng Li, Yanguang Cao
Summary: The response of metastatic lesions varies across different anatomic sites and therapies. High interlesion heterogeneity is associated with shorter survival, highlighting the potential benefits of targeted therapies in reducing heterogeneity and improving efficacy. Favorable responses in liver metastases are linked to extended overall survival, while lesions in other organs show less favorable outcomes.
Article
Oncology
Ting-Yu Chiang, Hung-Chih Hsu, Yih-Jong Chern, Chun-Kai Liao, Yu-Jen Hsu, Wen-Sy Tsai, Pao-Shiu Hsieh, Yu-Fen Lin, Hsiu-Lan Lee, Jeng-Fu You
Summary: The primary treatment for metastatic colorectal cancer (mCRC) includes targeted therapy and chemotherapy. Anti-EGFR antagonists can cause skin reactions in 50-70% of patients. Severe skin reactions may be linked to overall survival and progression-free survival, but the results are uncertain. A retrospective analysis of mCRC patients undergoing anti-EGFR therapy showed that the first-line treatment significantly affected overall survival and progression-free survival. There was a gender difference in the incidence of acne caused by anti-EGFR antagonists.
Article
Oncology
Greta Sommerhauser, Annika Kurreck, Alexander Beck, Uli Fehrenbach, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Mueller, Alexander O. Koenig, Ludwig F. v. Weikersthal, Eray Goekkurt, Siegfried Haas, Arndt Stahler, Volker Heinemann, Swantje Held, Annabel H. S. Alig, Stefan Kasper, Sebastian Stintzing, Tanja Trarbach, Dominik P. Modest
Summary: Depth of response (DpR) is an important end-point in clinical trials for patients with RAS wild-type metastatic colorectal cancer. This study investigated the overall DpR and its impact on prognosis and prediction in patients receiving induction therapy followed by maintenance therapy. The results showed that DpR to induction therapy was prognostic but not predictive for the efficacy of consecutive maintenance therapy.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Chiara Cremolini, Clara Montagut, Philippe Ronga, Filippo Venturini, Kensei Yamaguchi, Sebastian Stintzing, Alberto Sobrero
Summary: For patients with RAS wild-type metastatic colorectal cancer (mCRC), combination therapy with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies and chemotherapy is a standard first-line treatment option. Evidence suggests that anti-EGFR-resistant clones can decay after initial treatment, allowing for potential rechallenge or reintroduction in later treatment lines. Recent clinical studies have shown durable responses in some mCRC patients rechallenged with anti-EGFR monoclonal antibodies. This review summarizes the molecular rationale for rechallenge, examines the use of liquid biopsy for selecting rechallenge as a therapeutic option, and provides an overview of published and ongoing trials in this field.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
M. Buettelmann, R. D. Hofheinz, A. Kroecher, U. Ubbelohde, S. Stintzing, A. Reinacher-Schick, M. Bornhaeuser, G. Folprecht
Summary: Geriatric assessment (GA) has limited influence on treatment recommendations for elderly cancer patients, highlighting the need for further research and education in this area.
Review
Oncology
Erika Martinelli, Dirk Arnold, Andres Cervantes, Sebastian Stintzing, Eric Van Cutsem, Josep Tabernero, Julien Taieb, Harpreet Wasan, Fortunato Ciardiello
Summary: This article reviews the current knowledge and consensus management on the clinical management of BRAFV600E-mutant metastatic colorectal cancer (mCRC). The treatment landscape for this specific type of mCRC has changed greatly due to the emergence of molecular targeted therapies and immune checkpoint inhibitors. Tumor tissue analysis for DNA mismatch repair/microsatellite status and KRAS, NRAS, and BRAF mutational status is mandatory for appropriate clinical management and treatment decisions.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Alessandra Raimondi, Federico Nichetti, Arndt Stahler, Harpreet S. Wasan, Enrique Aranda, Giovanni Randon, Annika Kurreck, Angela M. Meade, Eduardo Diaz-Rubio, Monica Niger, Sebastian Stintzing, Federica Palermo, Tanja Trarbach, Michele Prisciandaro, Greta Sommerhauser, David Fisher, Federica Morano, Filippo Pietrantonio, Dominik P. Modest
Summary: This study analyzed the data from four randomized phase II trials and supported the use of 5-FU/LV plus anti-EGFR as the preferred maintenance regimen. The results also suggested an individualized approach to maintenance treatment based on tumor and patient characteristics.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Martin J. Raftery, Alexander Sebastian Franzen, Clarissa Radecke, Abdelhadi Boulifa, Guenther Schoenrich, Sebastian Stintzing, Jens-Uwe Blohmer, Gabriele Pecher
Summary: There is a medical need to develop new and effective therapies against triple-negative breast cancer (TNBC). We have developed a next-generation CAR targeting CD44v6 that incorporates IL-15 superagonist and checkpoint inhibitor molecules. CD44v6 CAR-NK cells demonstrated effective cytotoxicity against TNBC in 3D spheroid models and were resistant to immunosuppression by the tumor microenvironment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Arndt Stahler, Beeke Hoppe, Il-Kang Na, Luisa Keilholz, Lothar Mueller, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Ludwig Fischer von Weikersthal, Eray Goekkurt, Stefan Kasper, Andreas Jay Kind, Annika Kurreck, Annabel Helga Sophie Alig, Swantje Held, Anke Reinacher-Schick, Volker Heinemann, David Horst, Armin Jarosch, Sebastian Stintzing, Tanja Trarbach, Dominik Paul Modest
Summary: In patients with RAS wild-type mCRC, CMSs were evaluated as prognostic and predictive biomarkers. The addition of Pmab to FU/FA maintenance therapy was associated with longer PFS and OS in CMS2/4 tumors, whereas no benefit was observed in CMS1/3 tumors.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Christopher C. M. Neumann, Francois Schneider, Georg Hilfenhaus, Loredana Vecchione, Christian Benzing, Jana Ihlow, Uli Fehrenbach, Thomas Malinka, Ulrich Keilholz, Sebastian Stintzing, Uwe Pelzer
Summary: In addition to being risk factors for pancreatic cancer, parameters such as smoking, diabetes, or obesity might also act as potential prognostic factors for the survival of patients initially diagnosed with pancreatic cancer. By implementing one of the largest retrospective study cohorts, potential prognostic factors for survival were evaluated and various metabolic markers were identified.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Christopher C. M. Neumann, Francois Schneider, Georg Hilfenhaus, Loredana Vecchione, Matthaeus Felsenstein, Jana Ihlow, Dominik Geisel, Steffen Sander, Johann Pratschke, Sebastian Stintzing, Ulrich Keilholz, Uwe Pelzer
Summary: Inflammation markers, including NRL, PLR, LMR, CAR, and the new combined score IBI, have been identified as independent prognostic markers for overall survival in pancreatic cancer patients. These findings highlight the importance of inflammation in pancreatic cancer, provide easily accessible prognostic values, and may aid in patient stratification for trials targeting inflammation or immune response.
Article
Oncology
Till de Bortoli, Manuela Benary, Peter Horak, Mario Lamping, Sebastian Stintzing, Ingeborg Tinhofer, Serge Leyvraz, Reinhold Schaefer, Frederick Klauschen, Ulrich Keller, Albrecht Stenzinger, Stefan Froehling, Razelle Kurzrock, Ulrich Keilholz, Damian T. Rieke, Ivan Jelas
Summary: In this study, it was found that high tumour mutational burden (TMB) was associated with unfavorable outcome in patients receiving molecularly matched therapy. Patients with high TMB had significantly shorter overall survival and progression-free survival compared to those with low TMB. Additionally, a significant correlation was observed between co-occurring driver mutations and TMB.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Alexej Ballhausen, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Lothar Mueller, Alexander Otto Koenig, Ludwig Fischer von Weikersthal, Greta Sommerhaeuser, Annabel Helga Sophie Alig, Eray Goekkurt, Johanna Wanda Meyer-Knees, Annika Kurreck, Arndt Stahler, Swantje Held, Stefan Kasper, Kathrin Heinrich, Volker Heinemann, Sebastian Stintzing, Tanja Trarbach, Dominik Paul Modest
Summary: The addition of Panitumumab to fluorouracil and folinic acid maintenance therapy in patients with RAS wild-type metastatic colorectal cancer prolongs progression-free survival without negative impact on health-related quality of life.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Alexander J. Ohnmacht, Arndt Stahler, Sebastian Stintzing, Dominik P. Modest, Julian W. Holch, C. Benedikt Westphalen, Linus Hoelzel, Marisa K. Schuebel, Ana Galhoz, Ali Farnoud, Minhaz Ud-Dean, Ursula Vehling-Kaiser, Thomas Decker, Markus Moehler, Matthias Heinig, Volker Heinemann, Michael P. Menden
Summary: Precision medicine has revolutionized cancer treatments, but actionable biomarkers are still rare. In this study, the authors develop a framework called OncoBird to analyze the molecular and biomarker landscape of randomized controlled clinical trials, and apply it to a phase III trial investigating metastatic colorectal carcinoma patients.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
K. Heinrich, M. Karthaus, S. Fruehauf, U. Graeven, L. Mueller, A. O. Koenig, L. Fischer von Weikersthal, K. Caca, A. Kretzschmar, E. Goekkurt, S. Haas, A. H. S. Alig, A. Kurreck, A. Stahler, S. Held, G. Sommerhaeuser, V. Heinemann, S. Stintzing, T. Trarbach, D. P. Modest
Summary: PanaMa study conducted a sex-stratified analysis in patients with metastatic colorectal cancer (mCRC) and found that male patients showed a significant improvement in progression-free survival (PFS) after introducing Pmab in maintenance treatment compared to female patients, while female patients had a higher rate of adverse events.
Article
Oncology
Axel Muendlein, Christine Heinzle, Eva Maria Brandtner, Andreas Leiherer, Heinz Drexel, Tobias Dechow, Thomas Decker
Summary: This study included 47 patients with ER-positive/HER2-negative metastatic breast cancer who were studied before treatment with CDK4/6 inhibitors combined with endocrine therapy. The results showed that increased circulating GPC4 levels were significantly associated with advanced age, postmenopausal state, visceral metastases, and invasive lobular carcinoma. Circulating GPC4 was identified as a significant predictor of poor survival in metastatic breast cancer patients.
ONCOLOGY RESEARCH AND TREATMENT
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Felix O. Hofmann, Volker Heinemann, Melvin D'Anastasi, Alena B. Gesenhues, Nina Hesse, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Markus Moehler, Florian Kaiser, Tobias Heintges, Christoph Kahl, Frank Kullmann, Werner Scheithauer, Hartmut Link, Dominik P. Modest, Sebastian Stintzing, Julian W. Holch
Summary: This study aimed to improve the predictive accuracy of early tumor shrinkage (ETS) by using semi-automated volumetry instead of standard diametric measurements. The results showed that continuous diametric and volumetric ETS similarly predicted survival, and a threshold of 45% for volumetric ETS and 20% for diametric ETS accurately identified short-term survivors.
EUROPEAN RADIOLOGY
(2023)
